Voloridge Investment Management
SYRS

Voloridge Investment Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Voloridge Investment Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,131
Closed -$78K – 1460
2019
Q4 		$78K Buy
+1,131
New +$68.6K ﹤0.01% 1036

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Voloridge Investment Management's SYRS Position: Q1 2020 in Review

Voloridge Investment Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2020, closing a stake of 1,131 shares — an estimated $78K sold.

Voloridge Investment Management first reported a position in SYRS in Q4 2019 and held it in 1 quarter. The position peaked at $78K in Q4 2019. 64 funds tracked by Wall St. Rank hold SYRS as of Q1 2020.

  • Voloridge Investment Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Voloridge Investment Management sold 1,131 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $78K.
  • Voloridge Investment Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Voloridge Investment Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $78K in Q4 2019.
  • 64 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on Voloridge Investment Management's 13F filing for Q1 2020, filed 15 May 2020.